Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trial.
about
Use of massively parallel pyrosequencing to evaluate the diversity of and selection on Plasmodium falciparum csp T-cell epitopes in Lilongwe, MalawiVaccines against malariaDiversity of T cell epitopes in Plasmodium falciparum circumsporozoite protein likely due to protein-protein interactions.Mosquito cell line glycoproteins: an unsuitable model system for the Plasmodium ookinete-mosquito midgut interaction?Variation in the circumsporozoite protein of Plasmodium falciparum: vaccine development implications.Plasmodium vivax ookinete surface protein Pvs25 linked to cholera toxin B subunit induces potent transmission-blocking immunity by intranasal as well as subcutaneous immunizationMultiplicity of Plasmodium falciparum infection following intermittent preventive treatment in infants.Genetic variation in the Plasmodium falciparum circumsporozoite protein in India and its relevance to RTS,S malaria vaccine.Comparison of PfHRP-2/pLDH ELISA, qPCR and microscopy for the detection of plasmodium events and prediction of sick visits during a malaria vaccine study.A field trial to assess a blood-stage malaria vaccine.Genetic Diversity and Natural Selection of the Plasmodium knowlesi Circumsporozoite Protein Nonrepeat Regions.Molecular basis of allele-specific efficacy of a blood-stage malaria vaccine: vaccine development implicationsDesigning malaria vaccines to circumvent antigen variabilityGenetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria VaccineComparative population structure of Plasmodium falciparum circumsporozoite protein NANP repeat lengths in Lilongwe, MalawiEffect of malaria transmission reduction by insecticide-treated bed nets (ITNs) on the genetic diversity of Plasmodium falciparum merozoite surface protein (MSP-1) and circumsporozoite (CSP) in western Kenya.Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems.Harnessing genomics and genome biology to understand malaria biology.Clinical development of RTS,S/AS malaria vaccine: a systematic review of clinical Phase I-III trials.Genetic diversity and antibody responses against Plasmodium falciparum vaccine candidate genes from Chhattisgarh, Central India: Implication for vaccine development.Malaria Parasitemia and Parasite Density in Antiretroviral-Treated HIV-Infected Adults Following Discontinuation of Cotrimoxazole Prophylaxis.Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial.The RTS,S/AS01 malaria vaccine in children 5 to 17 months of age at first vaccination.Adjuvants: no longer a 'dirty little secret', but essential key players in vaccines of the future.RTS,S/AS01 malaria vaccine mismatch observed among Plasmodium falciparum isolates from southern and central Africa and globally.Genetic polymorphisms in the circumsporozoite protein of Plasmodium malariae show a geographical bias.Le vaccin antipaludique RTS,S/AS01 chez les enfants âgés de 5 à 17 mois au moment de la première vaccination
P2860
Q24617275-AE6DF979-D230-45A5-A114-663DA6808E03Q26995079-1FDB1B8F-F6F3-4C72-B3D7-CA1D70F466F8Q30430387-B965B127-0BFF-4682-A3D7-723764CBFBF5Q33818684-E917CDCB-7F2C-4618-95DD-1DEE9CA69E60Q33846126-67A773D7-26D0-4676-BC64-8FCA253527C3Q34119427-A56F3E50-F491-4CC1-B7D4-4057EA6082D8Q34128601-ADB1826B-B810-4B32-8742-97A5A16810C3Q34389610-70563AC4-F44F-49E1-A633-B7E3468C5E41Q34647777-1C8763B2-F139-45D8-95B9-9F491CCEF0A9Q35622737-182BFFF2-27A6-462C-912A-C735193B97E8Q35778593-DCB375C2-ADB5-4327-9447-C4DD9C3369B4Q36509831-FDD9B968-D74C-453B-AF76-657279FC9112Q36514853-AE11D504-8BE4-4E26-8144-59FA6D3FCF45Q36603519-1F52DED9-BD13-48DF-AC87-83AC6DE8E64FQ36932032-C13D1D3B-691E-4BB5-AE9C-A711C8C481D4Q37153165-23BB4506-330C-494B-8370-6978E7EF1E62Q37867102-48416F4C-1717-42C5-A086-CCFB531DDD50Q38001919-EC047A1A-1B17-4674-81B5-3F7D31841756Q38599514-ECA6DC66-4DB3-4D19-843A-45074A96AF4AQ40102169-397AA109-B8BC-4B35-A97C-C66D34F8A5A2Q40375985-B5BCE60A-62C2-40DF-98AF-FA5AAAFAF326Q44168825-E74D7D7F-378A-4E93-978E-64C5478EF636Q47977891-486C381A-D4C2-4765-A74F-A882A131E779Q51772228-E2747719-C7E6-4E58-8BEE-7C90B8343A6AQ53688944-3417EC13-9C12-4D98-BF6B-95D284BD56DBQ55716793-2D3A7F29-7C36-4B1C-869E-18D91AD48594Q58131059-9B1076FD-6044-453C-944C-D22B74A29966
P2860
Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trial.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Impact of RTS,S/AS02(A) and RT ...... alaria vaccine clinical trial.
@ast
Impact of RTS,S/AS02(A) and RT ...... alaria vaccine clinical trial.
@en
type
label
Impact of RTS,S/AS02(A) and RT ...... alaria vaccine clinical trial.
@ast
Impact of RTS,S/AS02(A) and RT ...... alaria vaccine clinical trial.
@en
prefLabel
Impact of RTS,S/AS02(A) and RT ...... alaria vaccine clinical trial.
@ast
Impact of RTS,S/AS02(A) and RT ...... alaria vaccine clinical trial.
@en
P2093
P2860
P50
P1433
P1476
Impact of RTS,S/AS02(A) and RT ...... alaria vaccine clinical trial.
@en
P2093
Amanda Leach
Carolyne M Kifude
Chris F Ockenhouse
D Gray Heppner
Douglas S Walsh
Joe D Cohen
John N Waitumbi
Marc Lievens
Mark E Polhemus
Samuel B Anyona
P2860
P356
10.1371/JOURNAL.PONE.0007849
P407
P577
2009-11-17T00:00:00Z